Presentation is loading. Please wait.

Presentation is loading. Please wait.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Published bySiegfried Fürst Modified over 5 years ago

Similar presentations

Presentation on theme: "Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic."— Presentation transcript:

1 Increased growth factor receptor expression in lungs and tumors of hypoxic mice.
Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Lysates from lungs obtained from urethane-treated mice exposed to normoxia or hypoxia and tumors from normoxic and hypoxic mice were analyzed for growth factor receptor expression by Western blotting. β-Actin was used as a loading control. A, levels of EGFR, PDGFR, and FGFR2. B, a graphical representation of levels for various treatments. C, VEGFR1, VEGFR2, Tie1, and Tie2. D, the graphical representation of the levels for various treatments. Data shown are mean ± SEM and * indicates P ≤ 0.05 for comparisons between normoxia and hypoxia (n = 3 for each treatment). Vijaya Karoor et al. Cancer Prev Res 2012;5: ©2012 by American Association for Cancer Research

Download ppt "Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic."

Similar presentations

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Dihydromyricetin decreases the sphere formation through downregulation of Sox2 in human osteosarcoma. Dihydromyricetin decreases the sphere formation through.

Dihydromyricetin decreases the sphere formation through downregulation of Sox2 in human osteosarcoma. Dihydromyricetin decreases the sphere formation through.
Pioglitazone inhibits aromatase expression in human preadipocytes.

Pioglitazone inhibits aromatase expression in human preadipocytes.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
HIF-1α is critically involved in hypoxia-induced CD137 upregulation.

HIF-1α is critically involved in hypoxia-induced CD137 upregulation.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
Supplementary Figure 1 A B C SW620 HT29 SW620

Supplementary Figure 1 A B C SW620 HT29 SW620
Mechanism of piperlongumine induced Sp downregulation.

Mechanism of piperlongumine induced Sp downregulation.
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
Expression of cGMP signaling components in polyps.

Expression of cGMP signaling components in polyps.
BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.

BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.
TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.
TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.
Variation in dUTPase expression in cell lines.

Variation in dUTPase expression in cell lines.
FOXO3a phosphorylation and expression.

FOXO3a phosphorylation and expression.

Similar presentations

Ads by Google